Hit-to-lead optimization of mouse Trace Amine Associated Receptor 1 (mTAAR1) agonists with a diphenylmethane-scaffold: Design, Synthesis, and biological study

Journal:	*Journal of Medicinal Chemistry*
Manuscript ID	jm-2016-01092q.R1
Manuscript Type:	Article
Date Submitted by the Author:	07-Sep-2016
Complete List of Authors:	Chiellini, Grazia; Università di Pisa, Department of Pathology Nesi, Giulia; Università di Pisa, Dipartimento di Farmacia Sestito, Simona; Università di Pisa, Dipartimento di Farmacia Chiarugi, Sara; Università di Pisa, Dipartimento di Farmacia Runfola, Massimiliano; Università di Pisa, Dipartimento di Farmacia Espinoza, Stefano; Istituto Italiano di Tecnologia, Dept of Neuroscience and Brain Technologies Sabatini, Martina; Università di Pisa, Department of Pathology Bellusci, Lorenza; Università di Pisa, Department of Pathology Laurino, Annunziatina; università degli studi di firenze, neurofarba Cichero, Elena; University of genoa, Pharmacy Gainetdinov, Raul; Istituto Italiano di Tecnologia, NBT; Institute of Translational Biomedicine, , St. Petersburg State University; Skolkovo Institute of Science and Technology Fossa, Paola; University of Genova, Farmacia Raimondi, Laura; università degli studi di firenze, neurofarba Zucchi, Riccardo; Università di Pisa, Dept of Pathology Rapposelli, Simona; Università di Pisa, Dipartimento di Farmacia

Hit-to-lead optimization of mouse Trace Amine Associated Receptor 1 (mTAAR1) agonists with a diphenylmethane-scaffold: Design, Synthesis, and biological study

Grazia Chiellini[1*], Giulia Nesi[2], Simona Sestito[2], Sara Chiarugi[2], Massimiliano Runfola[2], Stefano Espinoza[3], Martina Sabatini[1], Lorenza Bellusci[1], Annunziatina Laurino[4], Elena Cichero[5], Raul. R. Gainetdinov[6,7], Paola Fossa[5], Laura Raimondi[4], Riccardo Zucchi[1], Simona Rapposelli[2*].

[1]Dept. of Pathology, University of Pisa, Pisa, Italy, [2]Dept. of Pharmacy, University of Pisa, Pisa, Italy, [3]Department of Neuroscience and Brain Technologies, Istituto Italiano di Tecnologia, Genova, Italy, [4]Dept. of NEUROFARBA; Section of Pharmacology, University of Florence, Italy,[5]Dept. of Pharmacy, University of Genoa, Genoa, Italy. [6]Institute of Translational Biomedicine, St. Petersburg State University, St. Petersburg, 199034, Russia, [7]Skolkovo Institute of Science and Technology (Skoltech) Skolkovo, Moscow region, 143025, Russia.

Keywords: *m*TAAR1 agonist; diphenylmethane-scaffold; Thyronamine; T1AM; T0AM

Abstract.

The trace amine-associated receptor 1 (TAAR1) is a G-protein-coupled receptors (GPCR) potently activated by a variety of molecules besides trace amines (TAs), including thyroid hormone-derivatives like 3-iodothyronamine (T1AM), catechol-O-methyltransferase products like 3-methoxytyramine, and amphetamine-related compounds. Accordingly, TAAR1 is considered a promising target for medicinal development. To gain more insights into TAAR1 physiological functions and validation of its therapeutic potential we recently developed a new class of thyronamine-like derivatives. Among them compound SG2 showed high affinity and potent agonist activity at mouse TAAR1. In the present work we describe design, the synthesis and SAR study of a new series of compounds (**1-16**) obtained by introducing specific structural changes at key points of our lead-compound SG2 skeleton. Five of the newly synthesized compounds displayed mTAAR1 agonist activity higher than both SG2 and T1AM. Selected diphenylmethane analogs, namely **1** and **2,** showed potent functional activity in *in vitro* and *in vivo* models.

Introduction.

Thyronamine (TAM) is generally used to indicate a class of endogenous compounds deriving from thyroid hormones through metabolic reactions such as deiodination and decarboxylation [1]. Over the past decade, thyronamines have been recognized as ligands of trace amine - associated receptor 1 (TAAR1), and to date they represent a thriving research field. Currently, only two compounds that belong to the class of TAM have been identified *in vivo*: the 3-iodothyronamine (T1AM) and the thyronamine (T0AM). These compounds have been postulated to derive from thyroid hormone (T4) through deiodination and decarboxylation. T1AM is widely expressed in various tissues, such as brain, liver, heart and blood and it seems to be the most abundant thyronamine present in circulation[2].

Among several potential receptors, it has been proved that T1AM binds to TAAR1, a G-protein coupled receptor (GPCR) that has been identified in specific areas of the central nervous system and in some peripheral areas. The binding of T1AM to TAAR1 receptor leads to increase of cAMP levels by the activation of the adenylate cyclase. Further studies also highlighted that T1AM interact with other targets such as the biogenic amines transporters and the apoB100 protein. Thyronamines, and in particular T1AM, produce different functional effects, although their physiological role still remains unclear. Among the most significant effects attributed to T1AM are a hypothermic as well as negative inotropic and chronotropic cardiac effects. Moreover, endocrine and metabolic effects such as the modulation of insulin secretion, the inhibition of catecholamines resorption at the neuronal level and an increased metabolism of lipids at the expense of that of carbohydrates have been also described [3]. The wide variety of functions attributed to T1AM makes this molecule a potentially useful tool for the treatment of many diseases such as obesity, neuropsychiatric disorders and cancer. Unfortunately, TAMs are rapidly metabolized by different enzyme systems, such as amino-oxidase (MAO, SSAO), deiodinase (DIO3), sulfotransferase (SULT1A1 and SULT1A3), N-acetyltransferase, and glucuronidase. The action of these enzymes is

a limit to their therapeutic use. Consequently, the great therapeutic potential as well as the lack of new useful tools to elucidate the physiological function of T1AM, have pushed medicinal chemists to develop new synthetic analogues of T1AM.

Recently, with the aim of increasing the number of selective ligands for TAAR1 receptor and provide new tools to facilitate the understanding of the physiological functions of this receptor, we reported the design and synthesis of a new class of thyronamine-like compounds with a diphenylmethane scaffold, which proved to be synthetically more accessible than endogenous T1AM and T0AM[4, 5]. Within the small series of analogues previously synthesized, SG1 and SG2 were found to activate mouse TAAR1 receptor (mTAAR1) with a potency comparable to the corresponding endogenous ligands[4] (Figure 1). In particular, SG2, the analogue of T1AM, showed an EC_{50} = 240 nM comparable to T1AM (EC_{50} = 189 nM). In order to expand the SAR study for this new class of compounds, in the present work we describe the design and synthesis of compounds **1-16** obtained by introducing specific structural changes at key points of our lead-compound SG2 skeleton. The structural optimization process of the new thyronamine-like compounds was based on molecular docking studies that highlighted the main differences in the interaction between the endogenous ligand T1AM or the synthetic analogue SG2 with the mTAAR1 receptor binding site. The newly designed compounds were first screened *in vitro* for mTAAR1 activation. Five compounds (**1**,**2**,**4**,**7** and **8**) showed a higher potency than the lead molecule SG2, as well as, the endogenous ligand T1AM, with **1** and **2** being the most potent of the new series. These compounds were then evaluated both *in vitro* and *in vivo* to characterize their ability to modulate plasma glucose levels.



T1AM
mTAAR1 EC_{50} = 189nM



SG1 R=H
mTAAR1 EC_{50} = 1700nM
SG2 R=Me
mTAAR1 EC_{50} = 240nM

Figure 1. Structure of T1AM and the lead-molecules SG1 and SG2 with a diphenylmethane molecular scaffold

Results.

Design of new thyronamine-like analogues.

In our previous work, we explored the pharmacological profile of a new series of T_1AM diphenylmethane analogues, and among these compounds SG1 and SG2 were found to be a good mimic of the corresponding endogenous ligands T0AM and T1AM[4], respectively. In addition, a docking study was performed to investigate the main differences between T1AM and the lead diphenylmethane-analogue SG2 on mTAAR1 receptor binding. According to this study, T1AM appears to be highly stabilized in the binding site through the formation of two H-bonds between the protonated amino group of the ethylamine side chain and aspartic acid 102 (D102) and tyrosine 291 (Y291). Furthermore, T1AM established an additional H-bond between the hydroxyl-group on the outer ring and arginine 82 (R82), while no significant amino acid interactions were observed for the biaril-ethereal oxygen of T1AM. Notably, the SG2 derivative appeared to share most of the main mTAAR1/T1AM interactions [4]. Interestingly, the replacement of the hydroxyl group on the T1AM outer ring with an amino group, as in SG2, allowed the formation of a cation-π interaction, while no H-bonds to the R82 backbone oxygen atom were observed. Conceivably, the oxygen atom in the SG2-inner ring side chain may induce a shift of the molecule within the binding site, thus preventing the H-bond formation with R82. In order to expand the SAR study for this new class of

thyronamine analogues, we performed specific structural changes at key points of the SG2-molecular scaffold. Initially, to restore the H-bond with R82, the oxo-ethylamino side chain of SG2 was replaced with an ethylamine one (**1-6**). Among these new compounds, analogue **2** was synthesized to evaluate the effects induced by the recovery of the phenolic function as in T1AM. Additionally, to gain further insights on how the pattern of substitutions modulate the SG-analogues potency as mTAAR1 agonists, we investigated the following structure modifications: (a) the introduction of small alkyl substituents (Me, i-Pr) on both outer- and inner-rings (**4,6-10**); (b) the removal of the methylene-bridge, producing the diaryl-analogues **5** and **6**; (c) the introduction of a biguanide-moiety at the oxy-alkyl side chain (**15,16**) and finally (d) mono- and bis-N-acetylation (**3**, **9-15**). This last chemical modification has been suggested by a recent study conducted by Hoefig et al[6], showing that O-acetyl and N-acetyl derivatives of T1AM may be found in white adipose tissue and liver endogenous cells. Notably, N-Ac-T1AM was also found to be an endogenous cardioactive metabolite[6]. On the basis of these findings, the corresponding mono- and bis-N-acetylated analogues of SG1 and SG2 lead compounds (i.e. **11,12** and **13,14**, respectively) as well as the new acetylated products namely **3**, **9**,**10** and **15**, were synthetised.

Synthesis.

The derivatives **1-6** in which the oxo-ethylamino side chain of SG2 has been replaced with the ethylamine one have been synthesized as reported in Scheme 1. Briefly, the products **17-20** obtained by the palladium(0)-catalyzed Suzuki−Miyaura cross-coupling reaction of the trifluoroborate salt or boronic acid with the appropriate benzylbromide[4], reacted with $SOCl_2$ to give benzylchloride **21-24**. Subsequently, the nucleophilic substitution with NaCN afforded the compound **25-28** with high yields. As previously described[4], reduction of nitrile derivative with $LiAlH_4$ in the presence of a Lewis's acid afforded the diamine derivative **1,4-6**. Then, the treatment of **1** with a mixture of $Ac_2O/NaHCO_3$ provided the acetylanilide **3** (Scheme 1a).

Scheme 1



Reagents and conditions: a: $SOCl_2$, $CHCl_3$, rt, 2h; **b**: NaCN, H_2O/CH_3CN, mw; **c**: $LiAlH_4$, $AlCl_3$, THF, reflux, 12h; **d**: $Ac_2O/NaHCO_3$, rt, 1h, **e**: H_2, Pd-C, AcOH, 12h; **f:** $NaNO_2$, H_2SO_4, H_2O, 100°C, 1h.

Compound **2** was obtained starting from the acetonitrile derivative **25.** Reduction of the nitro-group with H_2 in the presence of 10% Pd-C afforded the aniline **29**. The subsequent hydrolysis of the diazonium salt obtained by reaction of **29** with $NaNO_2/H_2SO_4$ afforded the final product **2** (Scheme 1b).

The Suzuki Miyaura cross-coupling reaction of the 2,6-dimethyl-4-methoxy-boronic acid with the 4-nitrobenzyl bromide gave **31** which was demethylated with BBr_3 at 0°C affording to phenol **32**. The subsequent reaction of α-bromide-acetonitrile with **32** followed by reduction to the corresponding diamine-derivative gave the superior homolog of SG2 (**7**) (Scheme 2).

Scheme 2



Reagents and conditions: **a**: 4-Nitrobenzyl bromide, K_2CO_3, $PdCl_2$, Acetone/H_2O, rt, 72 h; **b**: BBr_3, DCM, 0°C, 1 h; **c**: $BrCH_2CN$, DMF, Cs_2CO_3, rt, 30'; **d**: $LiAlH_4$, $AlCl_3$, THF, reflux, 12 h.

Derivative **8-10** substituted with an i-Pr group in the outer ring and with a small N-alkyl (**8**) or N-acetyl-group (**9**,**10**) were synthesized starting from the cross coupling reaction of N-(4-(bromomethyl)-2-isopropylphenyl)acetamide (**34**) (see SI, Scheme S1) and the (4-(hydroxymethyl)-2-methylphenyl)fluoroboronate salt (Scheme 3). The tandem reactions with $SOCl_2$ and NaCN gave the nitrile derivative **37** with high yields. Subsequent reduction with $LiAlH_4/AlCl_3$ afforded the product **8,** which was then reacted with Ac_2O in the presence of $NaHCO_3$ in a ratio of 1:1 or 1:2 to give **9** and **10**, respectively.

As concerns the synthesis of the mono- and N-diacetylated derivatives **11-14** and the biguanide analogue of SG2 (**15** and **16**), the synthetic pathway as well as the procedures are reported in SI (Scheme S2).

SCHEME 3



Reagents and conditions: a) $PdCl_2$ dppf, Cs_2CO_3, H_2O/Diossano, 95°C, 24h; b) $SOCl_2$, $CHCl_3$, rt, 2h; c) NaCN, H_2O/CH_3CN, mw; d) $LiAlH_4$, $AlCl_3$, THF, reflux, 12 h; e) $Ac_2O/NaHCO_3$, rt,1h.

Receptor Activation.

mTAAR1 is coupled to stimulatory G protein and thus induces cAMP production in HEK293 upon agonist exposure. We measured the activity of the new compounds using a BRET-based assay as previously reported by us[4, 7]. The standard TAAR1 agonist β-PEA was used as reference compound (EC_{50} = 138 nM).

Initially, all **1-16** compounds were tested at a screening concentration of 10μM. Then, for the compounds that were found to be active, a dose-response curve was performed to calculate their corresponding EC_{50} values (Figure 2). As shown in Table 1, five compounds, namely **1,2,4,7** and **8**, appeared to be more potent than the lead compound SG2, as well as T1AM. All of them showed to be full agonists (Efficacy 100%). In particular, the more effective structure modifications resulted from the replacement of oxy-ethylamino side chain of SG2 with the ethylamino one (**1**) and the concomitant replacement of the amino group of the outer ring with the hydroxyl moiety (**2**).

Moreover, the addition of small alkyl groups in the inner ring of SG2 (**7**), as well as in the outer ring of the N-ethyl analogue of **1** (**8**), turned out to be successful, thus obtaining new compounds with a potency 2-fold higher than the lead compound SG2.

Table 1. Activity of the new diphenylmethane derivatives **1-6, 8-10** using BRET-based assay in mTAAR1 transfected HEK 293 cells. The EC_{50} values are expressed in nM.



1-6;8-10

compd	X	n	R	R_1	R_2	Y	mTAAR1 EC_{50} (nM)
1	NH_2	1	Me	H	H	NH_2	119
2	OH	1	Me	H	H	NH_2	98
3	NHAc	1	Me	H	H	NH_2	3100
4	NH_2	1	Me	Me	H	NH_2	158
5	NH_2	0	Me	H	H	NH_2	1180
6	NH_2	0	Me	Me	H	NH_2	633
8	NHEt	1	Me	H	i-Pr	NH_2	102
9	AcNEt	1	Me	H	i-Pr	NH_2	440
10	AcNEt	1	Me	H	i-Pr	NHAc	>10000

Table 2. Activity of the new diphenylmethane derivatives **7, 11-16** using BRET-based assay in mTAAR1 transfected HEK 293 cells. The EC_{50} values are expressed in nM.



7,11-16

compd	X	n	R	R_1	Y	mTAAR1 EC_{50} (nM)
7	NH_2	1	Me	Me	NH_2	134
11	NHAc	1	H	H	NH_2	>10000
12	NHAc	1	H	H	NHAc	>10000
13	NHAc	1	Me	H	NH_2	>10000
14	NHAc	1	Me	H	NHAc	>10000
15	NHAc	1	Me	H		>10000
16	NH_2	1	Me	H		>10000



Figure 2. Dose-response curves of the most active SG2-analogues. All the compounds are full agonists (Efficacy =100%)

Docking study.

In our previous work, we investigated T_1AM and a series of T_1AM analogues whose potency profile proved to be highly related to the presence of a proper basic feature linked to an aromatic core[4]. Indeed, our molecular modelling studies pointed out the relevance of a key salt bridge between the protonated amine group of SG1 and SG2 lead compounds and the highly conserved residue D102, together with a number of π–π stacking and cation-π contacts with the surrounding amino acids, as we previously detected in other series of TAAR1 ligands[8, 9].

These findings were supported by further homology modelling and docking studies we performed within the murine and human TAAR1 and TAAR5 receptors with respect to **T_1AM** ligand [10], and were also in accordance with the key role played by a proper basic feature included in any TAAR1

ligand, as reported in literature[11]. Notably, this information was definitively validated by the mutagenesis data involving the D102 residue, reported by Reese[12].

In order to rationalize the pharmacological results and refine the computational models, *in silico* docking studies on the most active compounds (**1,2,7** and **8**) were also performed, analysing their interactions with the putative receptor binding site (see SI, Table S1).

In agreement with the experimental data, our docking calculations revealed that the presence of the ethylamine chain appears to be the most effective choice, in particular within those series of compounds bearing a mono methyl-substituted inner ring (**1,2** and **8**). Based on a comparison with the prototype T1AM, the most promising newly designed analogues were overturned within the receptor binding site, maintaining in any case the key contact with D102 which is required for TAAR1 agonism (see SI, Figure S1)[12].

Notably, the most effective compounds **1** and **2** were characterized by a reversed docking mode when compared to that previously described for SG2[4]. Briefly, we originally highlighted the key role played by the protonated amino group of the ethyloxyamine side chain of SG2 in H-bonding with D102 and Y291, while the inner-phenyl group was engaged in π–π stacking with Y287. On the contrary, **1** (and **2**) displayed one H-bond between the aniline portion in the outer ring (or the hydroxyl group) and the D102 negative-charged side-chain, while the protonated basic side chain appeared to be involved in one H-bond and in a salt-bridge with T83 and D284, respectively, as shown in Figure 3a and 3b, respectively.



Figure 3. Docking mode of compounds SG2 (C atom cyan) and (a) **1** (C atom deep magenta) (b) **2** (C atom; coral) (c) **7** (C atom; light green) and (d) **8** (C atom; yellow) at the murine TAAR1 binding site. The most important residues are labelled.

The addition of a methyl-group in the inner-ring of SG2 led to a 2-fold increase of potency for 7, with an EC_{50} of 134nM vs 240 nM for SG2. The docking study showed that also **7** takes an overturned positioning with respect to SG2 in the binding site of mTAAR1 (Figure 3c).

Presumably, the presence of an additional substituent into the inner ring causes a shift of the molecule within the binding site promoting the interaction of the aniline nitrogen atom in the outer ring with D102 residue, while the side chain's nitrogen atom interacts with D284.

Finally, the introduction of small alkyl groups into the outer ring of **1** as in compound **8** didn't prevent the interaction between the nitrogen atom of aniline with D102 residue. Indeed, the EC_{50} value of **8** (EC_{50} =102nM) was comparable to that of **1** (EC_{50} = 119nM).

Modulation of hepatic glucose production.

The hyperglycemic effect observed after administration of exogenous T1AM had previously been attributed only to a modulation of insulin and/or glucagone secretion[13-15]. Recently, our study[16] showed that in human hepatocarcinoma cells (HepG2) T1AM treatment directly stimulated glucose production (EC_{50} = 0.84 μM), if adequate gluconeogenetic substrates were provided. Interestingly, the effect of T1AM on gluconeogenesis displayed a bell-shaped dose-response curve, suggesting a biphasic effect of T1AM on the modulation of gluconeogenesis. In the present study, the effects induced by two of the most potent new mTAAR1 agonists (i.e. **1** and **2**) on gluconeogenesis were assessed. Preliminarily, HepG2 cells were incubated with each compound at three different doses (0.1, 1 and 10μM). By comparison, similar experiments were performed using T1AM. As shown in Figure 4a, incubation with 0.1 and 1 μM of compound **2** induced a significant increase in glucose production ($P<0.01$), while a dose of 10μM induced a decreased stimulation of glucose production. On the other hand, compound **1** showed a dose-dependent increase of glucose production, which reached statistical significance only when compound **1** was used at the highest dose (10μM). As shown in Figure 4a, treatment of HepG2 cells with T1AM (0.1, 1 and 10 μM) confirmed the bell-shaped dose–response curve observed in our previous study[16]. To better define the dose dependence of **1** and **2** effects on glucose production additional experiments were carried out using a wider

range of doses for both compounds. As shown in Figure 4b the EC_{50} calculated for the effect on gluconeogenesis was in the submicromolar range for **2**, and in the supramicromolar range for **1**.

Figure 4: (a) Glucose production in HepG2 cell cultures that were incubated for 4 h in glucose production buffer after adding vehicle (DMSO) or compounds **1**, **2** and **T1AM**. Results are expressed as mean ± S.E.M. and are normalized to the total cell protein content determined in cell lysates. (n=3 in each case). (**b**) Glucose production in HepG2 cell in response to increasing concentrations of compound **1** (0.1, 1, 10 and 20 μM) and **2** (0.001, 0.01, 0.1, 1 and 10 μM). Results are mean ± S.E.M. and are normalized to the total cell protein content determined in cell lysates. (n=6 in each case).*P<0.05, **P<0.01 , ***P<0.001 by ANOVA.



Modulation of plasma glucose level.

As previously reported by us thyronamine-like analogues SG1 and SG2 demonstrated to be able to increase plasma glycaemia with a potency comparable to that of the corresponding endogenous thyronamine (i.e. T0AM and T1AM)[4]. Thus, in the present work the effects induced by **1** and **2** derivatives on plasma glucose level were also assessed.

Figure 5 shows that a single low dose (4.0 μg/kg, i.p.) of **1** or **2** significantly increases plasma glycaemia in CD-1 mice with a potency comparable to that previously shown by lead-compound SG2[4].

Figure 5. Effect of **1** and **2** on plasma glycaemia ($mg \cdot L^{-1}$) in CD1-mice. Plasma glucose was measured 15 min after test compound or vehicle injection (i.p.) in blood collected from the tail veins of 4 h starved mice (n = 8 in each group). Results are expressed as means mean±SEM.*P < 0.05 vs vehicle. ***P < 0.001 vs vehicle.



Conclusion

Our ongoing efforts to develop thyronamine-like analogues synthetically more accessible than endogenous thyronamines yielded a new class of potent mTAAR1 diphenylmethane ligands.

A medicinal chemistry optimization combined to docking studies were used starting from the molecular scaffold of our recently developed SG-compounds to design the new ligands. In particular, we investigated: (i) the replacement of the oxyethylamino side chain of SG2 with an ethylamino one (ii) the introduction of small alkyl substituents (Me, i-Pr) on both outer- and inner-rings and (iii) the recovery of the phenolic function as in T1AM. Overall these chemical modifications resulted in more potent mTAAR1 agonists when compared to T1AM, as well as, lead compound SG2. Taking into account the high structure similarity of compounds **1** and **2** with T1AM and their high affinity for mTAAR1, we further investigated their ability to modulate glucose levels using both *in vitro* (human HepG2 cells) and *in vivo* (CD1-mice) models. Both

compounds demonstrated potent functional activity. In conclusion, this paper describes for the first time the successful outcome of a hit-to-lead optimization process leading to the identification of new tools to explore the physiological and pharmacological functions of TAAR1.

Experimental Section

Chemistry.

General Material and Methods. Melting points were determined on a Kofler hot-stage apparatus and are uncorrected. Chemical shifts (δ) are reported in parts per million downfield from tetramethylsilane and referenced from solvent references; coupling constants J are reported in hertz. ^{1}H NMR and ^{13}C NMR spectra of all compounds were obtained with a Bruker TopSpin 3.2 400 MHz spectrometer. ^{13}C NMR spectra were fully decoupled. The following abbreviations are used: singlet (s), doublet (d), triplet (t), double−doublet (dd), and multiplet (m). The elemental compositions of the compounds agreed to within ±0.4% of the calculated values. Chromatographic separation was performed on silica gel columns by flash (Kieselgel 40, 0.040−0.063 mm; Merck) or gravity column (Kieselgel 60, 0.063−0.200 mm; Merck) chromatography. The ≥95% purity of the tested compounds was confirmed by combustion analysis. Reactions were followed by thin-layer chromatography (TLC) on Merck aluminum silica gel (60 F_{254}) sheets that were visualized under a UV lamp. The microwave-assisted procedures were carried out with a CEM Discover LabMate microwave. Evaporation was performed in vacuo (rotating evaporator). Sodium sulfate was always used as the drying agent. Commercially available chemicals were purchased from Sigma-Aldrich.

4-(4-(2-Aminoethyl)-2-methylbenzyl)aniline **(1).** To a suspension of $LiAlH_4$ (4.80 mL, 4.80 mmol) in THF was added dropwise a solution of $AlCl_3$ (639.6 mg, 4.80 mmol) in THF (20 mL), and the mixture was stirred for 5 min at r.t. A solution of **25** (142.0 mg, 0.53 mmol) in THF was added dropwise, and the mixture was heated at reflux for 12 h. The mixture was cooled to 0°C with an ice bath and added dropwise with water and then with 10% aqueous HCl. The mixture was extracted with diethyl ether, and the aqueous layer was made alkaline with NaOH 2N and extracted with

$CHCl_3$. The organic phase was separated, washed with brine, dried, filtered, and concentrated. The crude was purified by conversion in the corresponding hydrochloride salt. White solid. mp: 153-157°C. (67% yield). ^{1}H NMR (CD_3OD): δ 2.21 (s, 3H, CH_3); 2.94 (t, 2H, *J* = 7.8 Hz; CH_2); 3.17 (t, 2H, *J* = 7.8 Hz; CH_2); 4.03 (s, 2H, CH_2); 7.07-7.15 (m, 3H, Ar); 7.29 (d, 2H, *J* = 8.4 Hz, Ar); 7.34 (d, 2H, *J* = 8.4 Hz, Ar) ppm. ^{13}C NMR (CD_3OD): δ 143.44, 138.48, 138.37, 136.40, 131.89, 131.66, 131.35, 129.71, 127.54, 124.11, 41.99, 39.31, 34.09, 19.70 ppm. Anal. ($C_{16}H_{20}N_2 \cdot HCl$) C, H, N. % Calcd: 79.96 (C); 8.39 (H); 11.66 (N). % Found: 79.88 (C); 8.55 (H); 11.42 (N).

4-(4-(2-Aminoethyl)-2-methylbenzyl)phenol **(2).** Compound **2** was synthesized from **30** (109 mg, 0.46 mmol), $LiAlH_4$ (4.13 mL; 4.13 mmol) and $AlCl_3$ (550.8 mg, 4.13 mmol) in THF (18 mL) following the same procedure described above for the preparation of **1.** Yellow solid. mp: 138-140°C. (30% yield). ^{1}H NMR (CD_3OD): δ 2.18 (s, 3H, CH_3); 2.70 (t, 2H, *J* = 7.2 Hz; CH_2); 2.87 (t, 2H, *J* = 7.2 Hz; CH_2); 3.81 (s, 2H, CH_2); 6.64 (d, 2H, *J*=8.4 Hz, Ar); 6.84 (d, 2H, *J*=8.4 Hz, Ar); 6.94-7.03 (m, 3H, Ar) ppm. ^{13}C NMR (CD_3OD): δ 146.29, 139.28, 137.93, 137.82, 131.69, 131.64, 131.10, 130.31, 127.21, 116.88, 54.79, 39.22, 38.30, 19.74 ppm. Anal. ($C_{16}H_{19}NO$) C, H, N. % Calcd: 79.63 (C); 7.94 (H); 5.80 (N). % Found: 79.77 (C); 7.81 (H); 5.92 (N).

N-(4-(4-(2-Aminoethyl)-2-methylbenzyl)phenyl)acetamide **(3).** To a solution of **1** (50 mg, 0.18 mmoli) in saturated $NaHCO_3$ solution (0.06 mL) was added Ac_2O (0.02 mL, 0.18 mmoli). The mixture was left stirring at r.t. for 1 h, then, the mixture was dissolved in water and extracted with $CHCl_3$. The organic layer was dried and concentrated under reduced pressure. The crude product was purified by precipitation from MeOH/Et_2O to give **3.** White solid. mp: 132-136°C. (60% yield). ^{1}H NMR (CD_3OD): δ 2.10 (s, 3H, CH_3); 2.20 (s, 3H, $COCH_3$); 2.92 (t, 2H, *J* = 7.7 Hz; CH_2); 3.15 (t, 2H, *J* = 7.7 Hz; CH_2); 3.91 (s, 2H, CH_2); 7.04 (d, 2H, *J* = 8.4 Hz, Ar); 7.05-7.11 (m, 3H, Ar); 7.34 (d, 2H, *J* = 8.4 Hz, Ar) ppm. ^{13}C NMR (CD_3OD): δ 171.57, 139.37, 138.31, 137.77, 137.62, 135.91, 131.71, 131.52, 129.93, 127.33, 121.33, 42.01, 39.37, 34.09, 23.77, 19.74 ppm. Anal.

($C_{16}H_{20}N_2$·HCl) C, H, N. % Calcd: 79.96 (C); 8.39 (H); 11.66 (N). % Found: 79.88 (C); 8.55 (H); 11.42 (N).

4-(4-(2-Aminoethyl)-2,6-dimethylbenzyl)aniline **(4).** Compound **4** was synthesized from **26** (109 mg, 0.46 mmol), $LiAlH_4$ (4.13 mL; 4.13 mmol) and $AlCl_3$ (550.8 mg, 4.13 mmol) in THF (18 mL) following the same procedure described above for the preparation of **1.** The crude was purified by conversion in the corresponding hydrochloride salt. White solid, mp: 143-145°C. (68% yield). ^{1}H NMR (CD_3OD): δ 2.22 (s, 6H, CH_3); 2.91 (t, 2H, *J* = 7.7 Hz; CH_2); 3.18 (t, 2H, *J* = 7.7 Hz; CH_2); 4.11 (s, 2H, CH_2); 7.01 (s, 2H, Ar); 7.17 (d, 2H, *J* = 8.6 Hz, Ar); 7.30 (d, 2H, *J* = 8.6 Hz, Ar) ppm. ^{13}C NMR (CD_3OD): δ 142.77, 138.85, 136.31, 136.14, 130.58, 129.68, 129.61, 124.13, 42.00, 34.98, 34.12, 20.23 ppm. Anal. ($C_{17}H_{22}N_2$·HCl) C, H, N. % Calcd: 80.27 (C); 8.72 (H); 11.01 (N). % Found: 80.40 (C); 8.59 (H); 11.31 (N).

4'-(2-Aminoethyl)-2'-methyl-[1,1'-biphenyl]-4-amine **(5).** Compound **5** was synthesized from **27** (109 mg, 0.46 mmol), $LiAlH_4$ (4.13 mL; 4.13 mmol) and $AlCl_3$ (550.8 mg, 4.13 mmol) in THF (18 mL) following the same procedure described above for the preparation of **1.** The crude was purified by conversion in the corresponding hydrochloride salt. White solid, mp: 165-167°C. (70% yield). ^{1}H NMR (CD_3OD): δ 2.25 (s, 3H, CH_3); 2.99 (t, 2H, *J* = 7.8 Hz; CH_2); 3.22 (t, 2H, *J* = 7.8 Hz; CH_2); 7.19 (d, 2H, *J*=1.2 Hz, Ar); 7.25 (s, 1H, Ar); 7.51-7.46 (m, 4H, Ar) ppm. ^{13}C NMR (CD_3OD): δ 144.11, 140.55, 137.72, 137.02, 131.99, 131.21, 130.72, 127.48, 124.08, 41.92, 34.19, 20.43 ppm. Anal. ($C_{15}H_{18}N_2$·HCl) C, H, N. % Calcd: 79.61 (C); 8.02 (H); 12.38 (N). % Found: 80.00 (C); 8.10 (H); 12.22 (N).

4'-(2-Aminoethyl)-2',6'-dimethyl-[1,1'-biphenyl]-4-amine **(6).** Compound **6** was synthesized from **28** (109 mg, 0.46 mmol), $LiAlH_4$ (4.13 mL; 4.13 mmol) and $AlCl_3$ (550.8 mg, 4.13 mmol) in THF (18 mL) following the same procedure described above for the preparation of **1.** The crude was purified by conversion to the corresponding hydrochloride salt. White solid, mp: 171-173°C. (73% yield). ^{1}H NMR (CD_3OD): δ 2.00 (s, 3H, CH_3); 2.95 (t, 2H, *J* = 7.8 Hz; CH_2); 3.20 (t, 2H, *J* = 7.8 Hz;

CH_2); 7.07 (s, 2H, Ar); 7.30 (d, 2H, J = 8.4 Hz, Ar); 7.53 (d, 2H, J = 8.4 Hz, Ar) ppm. ^{13}C NMR (CD_3OD): δ 143.35, 140.41, 137.50, 137.27, 132.17, 130.72, 128.97, 124.52, 41.98, 34.21, 20.84 ppm. Anal. ($C_{16}H_{20}N_2$·HCl) C, H, N. % Calcd: 79.96 (C); 8.39 (H); 11.66 (N). % Found: 79.90 (C); 8.49 (H); 11.71 (N).

4-(4-(2-Aminoethoxy)-2,6-dimethylbenzyl)aniline **(7).** Compound **7** was synthesized from **33** (186.2 mg, 0.66 mmol), $LiAlH_4$ (6.87 mL, 6.87 mmol) and $AlCl_3$ (915.6 mg, 6.87 mmol) in THF (25 mL) following the same procedure described above for the preparation of **1.** The crude was purified by conversion to the corresponding hydrochloride salt. White solid, mp: 156-158°C. (75% yield). ^{1}H NMR (CD_3OD): δ 2.20 (s, 6H, CH_3); 3.37 (t, 2H, J = 5.0 Hz; CH_3); 4.07 (s, 2H, CH_2); 4.23 (t, 2H, J = 5.0 Hz; CH_2); 6.76 (s, 2H, Ar); 7.15 (d, 2H, J = 8.4 Hz, Ar); 7.30 (d, 2H, J = 8.4 Hz, Ar) ppm. ^{13}C NMR (CD_3OD): δ 156.50, 141.82, 138.32, 129.24, 129.09, 128.16, 122.72, 114.04, 63.74, 39.07, 33.21, 19.10 ppm. Anal. ($C_{17}H_{22}N_2O$·HCl) C, H, N. % Calcd: 75.52 (C); 8.20 (H); 10.36 (N). % Found: 75.60 (C); 8.07 (H); 10.40 (N).

4-(4-(2-Aminoethyl)-2-methylbenzyl)-N-ethyl-2-isopropylaniline **(8).** Compound **8** was synthesized from **37** (130.8 mg, 0.41 mmol), $LiAlH_4$ (1.84 mL, 1.84 mmol) and $AlCl_3$ (244.8 mg, 1.84 mmol) in THF (17 mL) following the same procedure described above for the preparation of **1.** The crude was purified by conversion in the corresponding hydrochloride salt. Brown solid, mp: 148-150°C. (67% yield). ^{1}H NMR (CD_3OD): δ 1.28 (d, 6H, J = 6.8 Hz, CH_3); 1.37 (t, 3H, J = 7.2 Hz, CH_3); 2.22 (s, 3H, CH_3); 2.93 (t, 2H, J=7.8 Hz, CH_2); 3.05-3.12 (m, 1H, CH); 3.16 (t, 2H, J = 7.8 Hz, CH_2); 3.43 (q, 2H, J = 7.2 Hz, CH_2); 4.04 (s, 2H, CH_2); 7.06-7.14 (m, 4H, Ar); 7.32 (d, 1H, J=8.4 Hz, Ar); 7.36 (d, 1H, J = 1.6 Hz, Ar) ppm. ^{13}C NMR (CD_3OD): δ 144.42, 143.51, 138.47, 138.36, 136.41, 131.87, 131.56, 131.00, 129.52, 128.88, 127.54, 124.53, 49.90, 41.97, 39.45, 34.11, 28.70, 24.43, 19.72, 11.38 ppm. Anal. ($C_{21}H_{30}N_2$·HCl) C, H, N. % Calcd: 81.24 (C); 9.74 (H); 9.02 (N). % Found: 81.36 (C); 9.65 (H); 9.11 (N).

N-(4-(4-(2-Aminoethyl)-2-methylbenzyl)-2-isopropylphenyl)-N-ethylacetamide **(9).** Compound **9** was synthesized from **8** (45.6 mg, 0.15 mmol), saturated $NaHCO_3$ solution (0.05 mL) and Ac_2O (0.01 mL, 0.15 mmol) following the same procedure described above for the preparation of **3.** The crude solid was collected by filtration and purified by conversion to the corresponding hydrochloride salt. Yellow solid. (30% yield). ^{1}H NMR (CD_3OD): δ 1.08-1.20 (m, 9H, CH_3, CH_3CH_2); 1.73 (s, 3H, $COCH_3$); 2.24 (s, 3H, CH_3); 2.90-2.96 (m, 3H, CH_2, CH); 3.02-3.07 (m, 1H, CH_2); 3.17 (t, 2H, *J* = 7.4 Hz, CH_2); 4.02 (s, 2H, CH_2); 4.11-4.18 (m, 1H, CH_2); 6.97-7.05 (m, 2H, Ar); 7.07-7.17 (m, 3H, Ar); 7.27 (s, 1H, Ar) ppm. ^{13}C NMR (CD_3OD): δ 173.03, 146.93, 143.12, 138.91, 138.71, 138.36, 136.21, 131.81, 131.53, 130.08, 128.87, 128.30, 127.47, 45.29, 42.01, 39.67, 34.10, 28.83, 24.48, 24.13, 22.59, 19.77, 12.99 ppm. Anal. ($C_{23}H_{32}N_2O$·HCl) C, H, N. % Calcd: 78.36 (C); 9.15 (H); 7.95 (N). % Found: 78.45 (C); 9.02 (H); 7.84 (N).

N-(4-(4-(2-Acetamidoethyl)-2-methylbenzyl)-2-isopropylphenyl)-N-ethylacetamide **(10).** Compound **10** was synthesized from **8** (45.6 mg, 0.15 mmol), saturated $NaHCO_3$ solution (0.05 mL) and Ac_2O (0.02 mL, 0.30 mmol) following the same procedure described above for the preparation of **3.** The reaction mixture was evaporated and the crude dissolved in AcOEt and washed twice with water. The evaporation of the organic collected phases gave final product as a white oil. (20% yield). ^{1}H NMR (CD_3OD): δ 1.10-1.20 (m, 9H, CH_3, CH_3CH_2); 1.73 (s, 3H, $COCH_3$); 1.90 (s, 3H, $COCH_3$); 2.21 (s, 3H, CH_3); 2.74 (t, 2H, *J* = 7.4 Hz, CH2); 2.90-2.96 (m, 1H, CH); 3.01-3.09 (m, 1H, CH_2); 3.37 (t, 2H, *J* = 7.4 Hz, CH_2); 4.00 (s, 2H, CH_2); 4.11-4.20 (m, 1H, CH_2); 6.99-7.09 (m, 5H, Ar); 7.25 (d, 1H, *J* = 1.2 Hz, Ar) ppm. ^{13}C NMR (CD_3OD): δ 173.20, 173.08, 146.89, 143.36, 138.82, 138.68, 137.88, 137.74, 131.86, 131.13, 130.06, 128.84, 128.28, 127.48, 45.34, 42.13, 39.71, 36.09, 28.86, 24.50, 24.16, 22.60, 22.52, 19.78, 13.00 ppm. Anal. ($C_{25}H_{34}N_2O_2$) C, H, N. % Calcd: 76.10 (C); 8.69 (H); 7.10 (N). % Found: 76.25 (C); 8.53 (H); 7.21 (N).

N-(4-(4-(2-Aminoethoxy)benzyl)phenyl)acetamide **(11).** Compound **11** was synthesized from **SG1**[4] (49.7 mg, 0.20 mmol), saturated $NaHCO_3$solution (0.07 mL) and Ac_2O (0.03 mL, 0.20 mmoli)

following the same procedure described above for the preparation of **3.** The crude product was purified by precipitation from MeOH/Et_2O to give **11.** White solid, mp: 132-136°C. (60% yield). ^{1}H NMR (CD_3OD): δ 2.10 (s, 3H, $COCH_3$); 3.34 (t, 2H, *J* = 5.2 Hz; CH_2); 3.87 (s, 2H, CH_2); 4.19 (t, 2H, *J* = 5.2 Hz; CH_2); 6.92 (d, 2H, *J* = 8.8 Hz, Ar); 7.10-7.14 (m, 4H, Ar); 7.42 (d, 2H, *J* = 8.4 Hz, Ar) ppm. ^{13}C NMR (CD_3OD): δ 171.59, 157.83, 138.90, 137.82, 136.02, 130.93, 130.03, 121.40, 115.70, 65.29, 41.30, 40.39, 23.76 ppm. Anal. ($C_{17}H_{20}N_2$·HCl) C, H, N. % Calcd: 71.81 (C); 7.09 (H); 9.85 (N). % Found: 71.88 (C); 7.15 (H); 9.92 (N).

N-(2-(4-(4-Acetamidobenzyl)phenoxy)ethyl)acetamide **(12).** Compound **12** was synthesized from **SG1** (47.0 mg, 0.19 mmol), saturated $NaHCO_3$ solution (0.14 mL) and Ac_2O (0.04 mL, 0.38 mmol) following the same procedure described above for the preparation of **3.** The crude product was purified by precipitation from MeOH/Acetone to give **12.** White solid, mp: 152-153°C. (60% yield). ^{1}H NMR (DMSO): δ 2.00 (s, 3H, $COCH_3$); 2.08 (s, 3H, $COCH_3$); 3.34-3.38 (m, 2H, CH_2); 3.79 (s, 2H, CH_2); 3.91 (t, 2H, *J* = 5.6 Hz; CH_2); 6.84 (d, 2H, *J* = 8.8 Hz, Ar); 7.08-7.10 (m, 4H, Ar); 7.45 (d, 2H, *J* = 8.8 Hz, Ar); 8.06 (br t, NH_2); 9.83 (br s, NH) ppm. ^{13}C NMR (CD_3OD): δ 173.59, 171.54, 158.58, 139.08, 137.78, 135.20, 130.82, 130.06, 121.39, 115.59, 67.53, 41.32, 40.26, 23.70, 22.46 ppm.. Anal. ($C_{19}H_{22}N_2O_3$·HCl) C, H, N. % Calcd: 69.92 (C); 6.79 (H); 8.58 (N). % Found: 69.88 (C); 6.67 (H); 8.61 (N).

N-(4-(4-(2-Aminoethoxy)-2-methylbenzyl)phenyl)acetamide **(13).** Compound **13** was synthesized from **SG2**[4] (50.0 mg, 0.19 mmol), saturated $NaHCO_3$ solution (0.07 mL) and Ac_2O (0.02 mL, 0.19 mmoli) following the same procedure described above for the preparation of **3.** The crude product was purified by precipitation from MeOH/Et_2O to give **13.** White solid, mp: 132-136°C. (60% yield). ^{1}H NMR (CD_3OD): δ 2.10 (s, 3H, CH_3); 2.19 (s, 3H, $COCH_3$); 3.34 (t, 2H, *J* = 5.0 Hz; CH_2); 3.89 (s, 2H, CH_2); 4.20 (t, 2H, *J* = 5.0 Hz; CH_2); 6.77 (dd, 1H, *J* = 2.4, 8.4 Hz, Ar); 6.83 (d, 1H, *J* = 2.4 Hz, Ar); 7.03 (d, 2H, *J* = 8.4 Hz, Ar); 7.06 (d, 1H, *J* = 8.4 Hz, Ar); 7.41 (d, 2H, *J* = 8.4 Hz, Ar) ppm. ^{13}C NMR (CD_3OD): δ 171.58, 158.00, 139.19, 138.03, 137.67, 133.61, 132.00, 129.79,

121.32, 117.73, 112.83, 65.18, 40.41, 38.93, 23.79, 19.96 ppm. Anal. ($C_{18}H_{22}N_2O_2$·HCl) C, H, N. % Calcd: 72.46 (C); 7.43 (H); 9.39 (N). % Found: 72.58 (C); 7.55 (H); 9.42 (N).

N-(2-(4-(4-Acetamidobenzyl)-3-methylphenoxy)ethyl)acetamide **(14).** Compound **14** was synthesized from **SG2** (50.0 mg, 0.19 mmol), saturated $NaHCO_3$ solution (0.14 mL) and Ac_2O (0.04 mL, 0.38 mmoli) following the same procedure described above for the preparation of **3.** The crude product was purified by precipitation from MeOH/Et_2O to give **14.** White solid, mp: 139-141°C. (56% yield). ^{1}H NMR (CD_3OD): δ 1.95 (s, 3H, CH_3); 2.09 (s, 3H, $COCH_3$); 2.16 (s, 3H, $COCH_3$); 3.53 (t, 2H, *J* = 5.6 Hz; CH_2); 3.87 (s, 2H, CH_2); 4.00 (t, 2H, *J* = 5.6 Hz; CH_2); 6.70 (dd, 1H, *J* = 2.4, 8.4 Hz, Ar); 6.74 (d, 1H, *J* = 2.4 Hz, Ar); 6.99-7.03 (m, 3H, Ar); 7.41 (d, 2H, *J* = 8.4 Hz, Ar) ppm. ^{13}C NMR (CD_3OD): δ 173.60, 171.53, 158.78, 139.01, 138.27, 137.66, 132.85, 131.94, 129.83, 121.32, 117.66, 112.72, 67.42, 40.30, 38.98, 23.70, 22.47, 19.96 ppm. Anal. ($C_{20}H_{24}N_2O_3$·HCl) C, H, N. % Calcd: 70.56 (C); 7.11 (H); 8.23 (N). % Found: 70.43 (C); 7.05 (H); 8.22 (N).

N-(4-(4-(2-(3-Carbamimidoylguanidino)ethoxy)-2-methylbenzyl)phenyl)acetamide **(15).** A mixture of **13** (32.3 mg, 0.16 mmol) and dicyandiamide (13.5 mg, 0.16 mmol) was heated to 160 °C for 100 min. The reaction mixture initially melts, then re-solidifies. The reaction was cooled to room temperature. The crude product was purified by crystallization from EtOH/Et_2O. Brown oil. (52% yield). ^{1}H NMR (CD_3OD): δ 2.09 (s, 3H, CH_3); 2.15 (s, 3H, $COCH_3$); 3.60 (t, 2H, *J* = 5.2 Hz; CH_2); 3.86 (s, 2H, CH_2); 4.05 (t, 2H, *J* = 5.2 Hz; CH_2); 6.65-6.77 (m, 3H, Ar); 7.01 (d, 2H, *J* = 8.0 Hz, Ar); 7.41 (d, 2H, *J* = 8.0 Hz, Ar) ppm. ^{13}C NMR (CD_3OD): δ 171.60, 162.12, 161.01, 158.56, 139.04, 138.20, 137.63, 133.00, 131.94, 129.80, 121.34, 117.63, 112.73, 67.55, 42.15, 38.94, 23.74, 19.97 ppm. Anal. ($C_{20}H_{26}N_6O_2$) C, H, N. % Calcd: 62.81 (C); 6.85 (H); 21.97 (N). % Found: 62.95 (C); 6.73 (H); 21.76 (N).

4-(4-(2-(3-Carbamimidoylguanidino)ethoxy)-2-methylbenzyl)aniline **(16).** To a solution of the amide **15** (0.57 mmol) in MeOH was added dropwise an aqueous solution of HCl 1N (0.2 mL); the

resulting solution was refluxed for 2h, then, after cooling, the solvent was evaporated. The residue was purified by precipitation from EtOH/Et_2O. Brown oil. (60% yield). ^{1}H NMR (CD_3OD): δ 2.17 (s, 3H, CH_3); 3.79 (t, 2H, *J* = 4.8 Hz; CH_2); 3.99 (s, 2H, CH_2); 4.21 (t, 2H, *J* = 4.8 Hz; CH_2); 6.79 (dd, 1H, *J* = 2.6, 8.2, Ar); 6.83 (d, 1H, *J* = 2.6 Hz, Ar); 7.08 (d, 1H, *J* = 8.2 Hz, Ar), 7.26 (d, 2H, *J* = 8.6 Hz, Ar), 7.32 (d, 2H, *J* = 8.6 Hz, Ar) ppm. Anal. ($C_{18}H_{24}N_6O$) C, H, N. % Calcd: 63.51 (C); 7.11 (H); 24.69 (N). % Found: 63.72 (C); 7.05 (H); 24.53 (N).

4-(Chloromethyl)-2-methyl-1-(4-nitrobenzyl)benzene **(21).** To a solution of alcohol **17** (96.0mg, 0.35 mmoli) in $CHCl_3$ at 0°C was added $SOCl_2$ (3.50 mmol; 0.25 mL). The reaction mixture was stirred for 2 h at room temperature, then, the solvent was evaporated. The residue was dissolved in H_2O and alkalized with NaOH 1N; and the aqueous layer was extracted with DCM. The organic phase was dried and the solvent was evaporated to give the corresponding crude **21**, which was used without further purification. Yellow oil. (80% yield). ^{1}H NMR ($CDCl_3$): δ 2.22 (s, 3H, CH_3); 4.08 (s, 2H, CH_2); 4.57 (s, 2H, CH_2); 7.09 (d, 1H, *J* = 7.6 Hz, Ar); 7.19-7.24 (m, 2H, Ar); 7.26 (d, 2H, *J*=7.4 Hz, Ar); 8.13 (d, 2H, *J*= 7.4 Hz, Ar) ppm. Anal. ($C_{15}H_{14}ClNO_2$) C, H, N. % Calcd: 65.34 (C); 5.12 (H); 5.08 (N). % Found: 65.52 (C); 5.03 (H); 5.24 (N).

5-(Chloromethyl)-1,3-dimethyl-2-(4-nitrobenzyl)benzene **(22).** Compound **22** was synthesized from **18** (224 mg, 0.87 mmol) and $SOCl_2$ (0.63 mL, 8.70 mmol) in $CHCl_3$ (25 mL) following the same procedure described above for the preparation of **21.** The crude was used without further purification. White oil. (76% yield). ^{1}H NMR ($CDCl_3$): δ 2.22 (s, 6H, CH_3); 4.14 (s, 2H, CH_2); 4.56 (s, 2H, CH_2); 7.13 (s, 2H, Ar); 7.15 (d, 2H, *J* = 8.5 Hz Ar); 8.11 (d, 2H, *J* = 8.5 Hz Ar) ppm. Anal. ($C_{16}H_{16}ClNO_2$) C, H, N. % Calcd: 66.32 (C); 5.57 (H); 4.83 (N). % Found: 66.49 (C); 5.59 (H); 5.11 (N).

4-(Chloromethyl)-2-methyl-4'-nitro-1,1'-biphenyl **(23).** Compound **23** was synthesized from **19** (125 mg, 0.51 mmol) and $SOCl_2$ (0.37 mL, 5.10 mmol) in $CHCl_3$ (25 mL) following the same procedure described above for the preparation of **21.** The crude was used without further purification. Yellow

oil. (83% yield). ^{1}H NMR ($CDCl_3$): δ 2.27 (s, 3H, CH_3); 4.61 (s, 2H, CH_2); 7.21 (d, 2H, *J* = 7.8 Hz, Ar); 7.31 (d, 1H, *J*=7.8 Hz, Ar); 7.34 (s, 1H, Ar); 7.48 (d, 2H, *J*=8.8 Hz, Ar); 8.29 (d, 2H, *J* = 8.8 Hz Ar) ppm. Anal. ($C_{14}H_{12}ClNO_2$) C, H, N. % Calcd: 64.25 (C); 4.62 (H); 5.35 (N). % Found: 63.91 (C); 4.68 (H); 5.40 (N).

4-(Chloromethyl)-2,6-dimethyl-4'-nitro-1,1'-biphenyl **(24).** Compound **24** was synthesized from **20** (134 mg, 0.52 mmol) and $SOCl_2$ (0.38 mL, 5.20 mmol) in $CHCl_3$ (25 mL) following the same procedure described above for the preparation of **21.** The crude was used without further purification. White oil. (81% yield). ^{1}H NMR ($CDCl_3$): δ 2.02 (s, 6H, CH_3); 4.58 (s, 2H, CH_2); 7.17 (s, 2H, Ar); 7.33 (d, 2H, *J* = 8.8 Hz Ar); 8.31 (d, 2H, *J* = 8.8 Hz Ar) ppm. Anal. ($C_{15}H_{14}ClNO_2$) C, H, N. % Calcd: 65.34 (C); 5.12 (H); 5.08 (N). % Found: 65.40 (C); 5.59 (H); 5.31 (N).

2-(4-(4-Aminobenzyl)-3-methylphenyl)acetonitrile **(25).** To a solution of chloro compound **21** (78.0 mg; 0.46 mmol) in CH_3CN (0.62 mL) was added NaCN (45.1 mg; 0.92 mmol) in H_2O (0.21 mL). The mixture was submitted to microwave irradiation (150W, 100°C, 20 min). After cooling the solution was extracted with DCM. Organic phase was dried and evaporated to dryness. Yellow oil. (86% yield). ^{1}H NMR ($CDCl_3$): δ 2.22 (s, 3H, CH_3); 3.71 (s, 2H, CH_2); 4.07 (s, 2H, CH_2); 7.09-7.18 (m, 3H, Ar); 7.25 (d, 2H, *J* = 8.6 Hz, Ar); 8.13 (d, 2H, *J*= 8.6 Hz, Ar) ppm. Anal. ($C_{16}H_{14}N_2O_2$) C, H, N. % Calcd: 72.16 (C); 5.30 (H); 10.52 (N). % Found: 72.34 (C); 5.02 (H); 10.65 (N).

2-(3,5-Dimethyl-4-(4-nitrobenzyl)phenyl)acetonitrile **(26).** Compound **26** was synthesized from **22** (193 mg, 0.70 mmol) and NaCN (68.5 mg, 1.40 mmol) in CH_3CN/H_2O (0.94 mL/0.32 mL) following the same procedure described above for the preparation of **25.** The crude was used without further purification. White oil. (70% yield). ^{1}H NMR ($CDCl_3$): δ 2.22 (s, 6H, CH_3); 3.70 (s, 2H, CH_2); 4.13 (s, 2H, CH_2); 7.06 (s, 2H, Ar); 7.14 (d, 2H, *J* = 8.6 Hz Ar); 8.11 (d, 2H, *J* = 8.6 Hz Ar) ppm. Anal. ($C_{17}H_{16}N_2O_2$) C, H, N. % Calcd: 72.84 (C); 5.75 (H); 9.99 (N). % Found: 72.60 (C); 5.60 (H); 10.02 (N).

2-(2-Methyl-4'-nitro-[1,1'-biphenyl]-4-yl)acetonitrile **(27).** Compound **27** was synthesized from **23** (95.0 mg, 0.61 mmol) and NaCN (59.8 mg, 1.22 mmol) in CH_3CN/H_2O (0.82 mL/0.30 mL) following the same procedure described above for the preparation of **25.** The crude was used without further purification. Yellow oil. (86% yield). ^{1}H NMR ($CDCl_3$): δ 2.28 (s, 3H, CH_3); 3.78 (s, 2H, CH_2); 7.21-7.31 (m, 3H, Ar); 7.47 (d, 2H, *J* = 7.0 Hz, Ar); 8.29 (d, 2H, *J* = 7.0 Hz Ar) ppm. Anal. ($C_{15}H_{12}N_2O_2$) C, H, N. % Calcd: 71.42 (C); 4.79 (H); 11.10 (N). % Found: 71.41 (C); 4.80 (H); 11.15 (N).

2-(2,6-Dimethyl-4'-nitro-[1,1'-biphenyl]-4-yl)acetonitrile **(28).** Compound **28** was synthesized from **24** (101 mg, 0.36 mmol) and NaCN (35.3 mg, 0.72 mmol) in CH_3CN/H_2O (0.49 mL/0.16 mL) following the same procedure described above for the preparation of **25.** The crude was used without further purification. Pale yellow oil. (81% yield). ^{1}H NMR ($CDCl_3$): δ 2.02 (s, 6H, CH_3); 3.73 (s, 2H, CH_2); 7.10 (s, 2H, Ar); 7.32 (d, 2H, *J* = 8.6 Hz Ar); 8.31 (d, 2H, *J* = 8.6 Hz Ar) ppm. Anal. ($C_{16}H_{14}N_2O_2$) C, H, N. % Calcd: 72.16 (C); 5.30 (H); 10.52 (N). % Found: 72.40 (C); 5.59 (H); 10.31 (N).

2-(4-(4-Aminobenzyl)-3-methylphenyl)acetonitrile **(29).** A solution of **25** (136 mg, 0.5 mmoli) in AcOH (0.5mL) was hydrogenated in the presence of 10% Pd-C (28.3 mg), for 12 h. Then the catalyst was filtered off, and the solvent was removed to dryness to give a crude product that was used in the subsequent step without any further purification. Yellow oil. (80% yield). ^{1}H NMR ($CDCl_3$) δ: 2.24 (s, 3H, CH_3); 3.68 (s, 2H, CH_2); 3.85 (s, 2H, CH_2); 6.61 (d, 2H, *J* = 8.4 Hz, Ar); 6.88 (d, 2H, *J* =8.4 Hz, Ar); 7.06-7.12 (m, 3H, Ar) ppm. Anal. ($C_{16}H_{16}N_2$) C, H, N. % Calcd: 81.32 (C); 6.82 (H); 11.85 (N). % Found: 81.45 (C); 6.73 (H); 11.98 (N).

2-(4-(4-Hydroxybenzyl)-3-methylphenyl)acetonitrile **(30).** To a mixture of aniline derivative **29** (63.0 mg, 0.26 mmoli) in H_2O was added dropwise with H_2SO_{4conc} (0.06 mL) and the mixture was stirred at room temperature for 20min. Then a solution $NaNO_2$ (17.9 mg, 0.26 mmoli) in H_2O (0.19 ml) was added dropwise to the reaction mixture. The resulting solution was stirred for 1 h at 100°C.

The mixture was cooled to room temperature, and the residue diluted with AcOEt and washed with brine. The collected organic layers were dried and evaporated to give compound **30** that was directly used in the next step. Yellow oil. (60% yield). ^{1}H NMR ($CDCl_3$) δ: 2.22 (s, 3H, CH_3); 3.84 (s, 2H, CH_2); 4.06 (s. 2H, CH_2); 7.14-7.19 (m, 3H, Ar); 7.27-7.33 (m, 4H, Ar) ppm. Anal. ($C_{16}H_{15}NO$) C, H, N. % Calcd: 80.98 (C); 6.37 (H); 5.90 (N). % Found: 80.72 (C); 6.51 (H); 5.84 (N).

5-Methoxy-1,3-dimethyl-2-(4-nitrobenzyl)benzene **(31).** To a solution of 4-methoxy-2,6-dimethylphenylboronic acid (473 mg, 2.63 mmol) in acetone/H_2O 1:1 (4 mL) was added, under nitrogen flux, *p*-nitrobenzyl bromide (569 mg, 2.63 mmol), K_2CO_3 (1.24 g, 6.58 mmol) and a catalytic amount of $PdCl_2$. The resulting mixture was stirred at r.t. for 62 h in a sealed vial. The crude mixture was evaporated and then diluted with water and extracted with Et_2O. The organic phase was dried over sodium sulfate and concentrated under vacuum. The crude residue was purified by column chromatography Petroleum Ether /AcOEt (99:1), affording **31.** Yellow oil. (49% yield). ^{1}H NMR ($CDCl_3$): δ 2.19 (s, 6H, CH_3); 3.80 (s, 3H, OCH_3); 4.08 (s, 2H, CH_2); 6.65 (s, 2H, Ar); 7.16 (d, 2H, J = 8.8 Hz, Ar); 8.09 (d, 2H, J = 8.8 Hz, Ar) ppm. Anal. ($C_{16}H_{17}NO_3$) C, H, N. % Calcd: 70.83 (C); 6.32 (H); 5.16 (N). % Found: 71.01 (C); 6.12 (H); 5.00 (N).

3,5-Dimethyl-4-(4-nitrobenzyl)phenol **(32).** A solution of **31** (0.39 mmol) in anhydrous DCM (1.5 mL) was cooled to −78 °C and treated dropwise with a solution of BBr_3 in DCM (3.94 mL, 1.24 mmol); the resulting solution was stirred at the same temperature for 5 min and at 0 °C for 1 h. The mixture was then diluted with water and extracted with DCM. Organic phase was dried and evaporated to give the product **32**. Pale yellow oil. (64% yield). ^{1}H NMR ($CDCl_3$): δ 2.16 (s, 6H, CH_3); 4.06 (s, 2H, CH_2); 6.59 (s, 2H, Ar) 7.16 (d, 2H, J=8.8 Hz, Ar); 8.10 (d, 2H, J=8.8 Hz, Ar) ppm. Anal. ($C_{15}H_{15}NO_3$) C, H, N. % Calcd: 70.02 (C); 5.88 (H); 5.44 (N). % Found: 70.00 (C); 5.91 (H); 5.63 (N).

2-(3,5-Dimethyl-4-(4-nitrobenzyl)phenoxy)acetonitrile ***(33).*** To a mixture of cesium carbonate (725 mg, 2.22 mmol) and phenol derivative **32** (0.44 mmol) in 50 mL of DMF was added $BrCH_2CN$ (0.03 mL, 0.44 mmol). The reaction mixture was stirred for 30 min at r.t., poured into 100mL of cold HCl 1N and extracted with AcOEt. The organic phase was dried and evaporated to give the product **33**. White oil. (98% yield). ^{1}H NMR ($CDCl_3$): δ 2.22 (s, 6H, CH3); 4.10 (s, 2H, CH_2); 4.77 (s, 2H, CH_2CN); 6.73 (s, 2H, Ar); 7.15 (d, 2H, *J* = 8.8, Ar); 8.11 (d, 2H, *J*=8.8 Hz, Ar) ppm. Anal. ($C_{17}H_{16}N_2O_3$) C, H, N. % Calcd: 68.91 (C); 5.44 (H); 9.45 (N). % Found: 68.65 (C); 5.52 (H); 9.65 (N)

N-(4-(4-(Hydroxymethyl)-2-methylbenzyl)-2-isopropylphenyl)acetamide ***(35).*** To a solution of trifluoro(4-(hydroxymethyl)-2-methylphenyl)borane salt (509 mg; 2.38 mmol) in dioxane/H_2O 9:1 (4 mL) was added, under nitrogen atmosphere, N-(4-(bromomethyl)-2-isopropylphenyl)acetamide **34** (513 mg; 2.38 mmol), cesium carbonate (2.30 g; 7.1 mmol) and $PdCl_2$dppf (34.8 mg; 0.05 mmol). The resulting mixture was stirred at 95°C for 24 h in a sealed vial. The crude mixture was evaporated and then diluted with water and extracted with DCM. The organic phase was dried over sodium sulfate and the solvent removed. The crude product was chromatographed on a silica gel column, eluting with Petroleum Ether/AcOEt (9:1). Brown oil. (50% yield). ^{1}H NMR ($CDCl_3$): δ δ 1.20 (d, 6H, *J* = 6.8 Hz, CH_3); 2.19 (s, 3H, CH_3); 2.26 (s, 3H, CH_3CO); 2.96-3.03 (m, 1H, CH); 3.94 (s, 2H, CH_2); 4.65 (s, 2H, CH_2); 6.90 (dd, 1H, *J* = 1.6, 8.0 Hz, Ar), 7.05-7.09 (m, 2H, Ar); 7.13 (d, 1H, *J* = 8.0 Hz, Ar); 7.17 (s, 1H, Ar); 7.47 (d, 1H, *J* = 8.0 Hz) ppm. Anal. ($C_{20}H_{25}NO_2$) C, H, N. % Calcd: 77.14 (C); 8.09 (H); 4.50 (N). % Found: 77.39 (C); 8.21 (H); 4.64 (N).

N-(4-(4-Cchloromethyl)-2-methylbenzyl)-2-isopropylphenyl)acetamide ***(36).*** Compound **36** was synthesized from **35** (208 mg, 0.67 mmol) and $SOCl_2$ (0.49 mL, 6.70 mmol) in $CHCl_3$ (25 mL) following the same procedure described above for the preparation of **21.** The crude was used without any further purification. Brown oil. (70% yield). ^{1}H NMR ($CDCl_3$): δ 1.20 (d, 6H, *J* = 6.8 Hz, CH_3); 2.20 (s, 3H, CH_3); 2.26 (s, 3H, CH_3CO); 2.96-3.03 (m, 1H, CH); 3.93 (s, 2H, CH_2); 4.57

(s, 2H, CH_2); 6.90 (d, 1H, *J* = 6.0 Hz, Ar), 7.02-7.09 (m, 2H, Ar); 7.15 (d, 1H, *J* = 8.4 Hz, Ar); 7.19 (s, 1H, Ar); 7.48 (d, 1H, *J* = 8.4 Hz) ppm. Anal. ($C_{20}H_{24}ClNO$) C, H, N. % Calcd: 72.82 (C); 7.33 (H); 4.25 (N). % Found: 72.61 (C); 7.42 (H); 4.13 (N).

N-(4-(4-(Cyanomethyl)-2-methylbenzyl)-2-isopropylphenyl)acetamide ***(*37*).*** Compound **37** was synthesized from **36** (152 mg, 0.46 mmol) and NaCN (45.3 mg, 0.92 mmol) in CH_3CN/H_2O (1.86 mL/0.63 mL) following the same procedure described above for the preparation of **25.** The crude was used without any further purification. Yellow oil. (88% yield). ^{1}H NMR ($CDCl_3$): δ 1.20 (d, 6H, *J* = 6.8 Hz, CH_3); 2.19 (s, 3H, CH_3); 2.25 (s, 3H,CH_3CO); 2.96-3.03 (m, 1H, CH); 3.70 (s, 2H, CH_2); 3.93 (s, 2H, CH_2); 6.89 (d, 1H, *J* = 8.0 Hz, Ar), 7.03-7.09 (m, 3H, Ar); 7.12 (s, 1H, Ar); 7.48 (d, 1H, J=8.0 Hz, Ar) ppm. Anal. ($C_{21}H_{24}N_2O$) C, H, N. % Calcd: 78.71 (C); 7.55 (H); 8.74 (N). % Found: 78.85 (C); 7.41 (H); 8.90 (N).

Molecular modeling

All compounds were built, parameterised (Gasteiger-Huckel method) and energy minimised within MOE using MMFF94 forcefield [MOE: Chemical Computing Group Inc. Montreal. H3A2R7 Canada. http://www.chemcomp.comp]. For all compounds, the protonated form was considered for the *in silico* analyses.

Docking studies. Docking studies were performed starting from the in-house homology model of the murine TAAR1 receptor[4], built on the X-ray structure of the human β2- adrenoreceptor (PDB ID: 3PDS)[17], following a protocol we previously discussed exploring the binding mode of other TAAR1 ligands[8, 9]. Briefly, the most promising compounds were docked into the putative ligand binding site by means of the Surflex docking module implemented in Sybyl-X1.0[18].

Surflex-Dock uses an empirically derived scoring function based on the binding affinities of X-ray protein-ligand complexes. The final total score listed by Surflex-Dock is a weighted sum of non-linear functions involving van der Waals surface distances between the appropriate pairs of exposed

protein and ligand atoms, including hydrophobic, polar, repulsive, entropic and solvation and crash terms represented in terms of a total score conferred to any calculated conformer. Then, for all the compounds, the best docking geometries (selected on the basis of the SurFlex scoring functions) were refined by ligand/receptor complex energy minimization (CHARMM27) by means of the MOE software.

In vitro Biological studies

Reagents. All cell culture reagents and buffers were from Invitrogen (Carlsbad, CA) and Sigma (St. Louis, MO). Coelenterazine *h* was purchased from Promega (Madison, WI). Plasmid containing the cDNA for the mTAAR1 were generously donated from Hoffman-La Roche. EPAC cAMP BRET sensor was produced as described[19].

Cell Culture and BRET experiment

Human embryonic kidney 293 cells (HEK293T) were maintained in Dulbecco's Modified Eagle's medium supplemented with 10% (vol/vol) of FBS, 2 mM l-glutamine and 0.05 mg/ml of gentamicin at 37°C in a humidified atmosphere at 95% air and 5% CO_2. Transient transfections were performed 24 h after cells seeding using lipofectamine 2000 protocol (Invitrogen). 5µg of mTAAR1 and 4µg of EPAC for each milliliter of transfection solution were used for the experiments. For the BRET experiments the cells were plated, 6 hours after transfection, in poly-D-lysine coated 96-well microplates at a density of 70,000 cells per well in phenol red free Minimum Essential Medium containing 2% of FBS, 10 mM Hepes, 2 mM L-glutamine. The cells were then cultured for an additional 24 h. BRET experiment was conducted as already described [7]. Briefly, for time course experiments, the plate was read immediately after the addition of the agonist and for approximately 20 minutes. All the compounds were tested for screening at the initial concentration of 10 µM. Then, for active compounds, a dose response was performed, in order to calculate the EC_{50} values. All the experiments were conducted in presence of the phosphodiesterase inhibitor IBMX (Sigma) at the final concentration of 200 µM. Readings were collected using a Tecan Infinite

instrument that allows the sequential integration of the signals detected in the 465 to 505nm and 515 to 555 nm windows using filters with the appropriate band pass and by using iControl software. The acceptor/donor ratio was calculated as previously described [20]. Curve was fitted using a non-linear regression and one site specific binding with GraphPad Prism 5. Data are representative of 4-5 independent experiments and are expressed as means±SEM.

Cell culture and glucose production evaluation. Human hepatocellular carcinoma cells (HepG2), obtained from American Type Culture Collection (Manassas, VA, USA), were cultured in DMEM supplemented with 10% (v/v) fetal bovine serum, 1 mM pyruvate, 100 U/ml penicillin, and 100 mg/ml streptomycin at 37°C in a humidified atmosphere containing 5% CO_2 and sub-cultured before confluence. To assess glucose release, HepG2 were seeded into six-well plates ($5x10^5$ cells/well) and grown to 80% of confluence with standard medium. As previously described[9], before treatment cells were washed twice with PBS and then exposed for 4 h to test compounds (**1** and **2**) (0.1, 1 and 10 μM) in 1 ml DMEM base, glucose- and phenol red-free, containing 100 U/ml penicillin,100 mg/ml streptomycin, and 4 mM L-glutamine, supplemented with 2 mM sodium pyruvate and 20 mM sodium lactate (glucose production buffer) at 37 ^oC in 5% CO_2. Exogenous T1AM (0.1, 1 and 10 μM) was used as control. Control cells were incubated with supplemented DMEM containing DMSO (1–2 μl/well). Cell culture medium was then collected and glucose concentration was measured with a colorimetric glucose assay kit (GAHK-20, Sigma-Aldrich), following manufacturer's instruction. Glucose concentrations were referred to the total protein content (Bradford 1976) of whole HepG2 lysates. Results are expressed as the mean ± S.E.M. Differences between groups were analyzed by ANOVA. The threshold of statistical significance was set at $P<0.05$. GraphPad Prism version 6.0 for Windows (GraphPad Software, San Diego, CA, USA) was used for data processing and statistical analysis.

Measurement of plasma glycaemia

This investigation and animal use procedure complied with the National Institutes of Health Guide for the Care and Use of Laboratory Animals (NIH Publications no. 80-23, revised 1996) and were approved by the Animal Care Committee of the Department of Pharmacology, University of Florence, in compliance with the European Communities Council Directive of 24 November 1986 (86/609/EEC). All efforts were made to minimize the number of animals used and their suffering.

Glycaemia was monitored in blood collected from the tail vein of 4 h fasted male mice (CD1 strain, 20-30g, from Envigo, Italy), who had received **1** and **2** (1.32, 4 and 11 μg.kg-1 i.p.) or saline (i.p.) (n = 8 in each group). Glycaemia was evaluated by a glucorefractometer 15 min after the i.p. injections, as described[4]. Data are expressed as mean ± SEM of independent experiments. Statistical analysis was performed by oneway ANOVA, followed by Student–Newman–Keuls multiple comparison post hoc test; the threshold of statistical significance was set at $P<0.05$. Data analysis was performed by GraphPad Prism 6.0 statistical program (GraphPad software, San Diego, CA, USA). The acceptor/donor ratio was calculated as previously described [20]. Curve was fitted using a non-linear regression and one site specific binding with GraphPad Prism 5. Data are representative of 4-5 independent experiments and are expressed as means±SEM.

ASSOCIATED CONTENT

Supporting Information. Synthetic pathways and procedures for the preparation of compound **34** and derivatives **11-16.** ^{1}H NMR and ^{13}C NMR spectra of final compounds. The Supporting Information is available free of charge on the ACS Publications website

AUTHOR INFORMATION

Corresponding Authors: *For G.C.: phone, +39 050 2218677; E-mail, g.chiellini@bm.med.unipi.it.

*For S.R.: phone, +39 050 2219582; E-mail, simona.rapposelli@farm.unipi.it.

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

We thank Prof. Anna Maria Raspolli Galletti from the Department of Chemistry, University of Pisa (Italy) for allowing us to perform microwave-assisted reactions in her lab, and Prof. Thomas Scanlan for supplying us T1AM. This work was supported by a local grant from the University of Pisa (to G.C. and S.R.) and by the Russian Science Foundation (project N14-25-00065) (to R.R.G.)

ABBREVIATION USED

T1AM, 3-iodothyronamine; T0AM, thyronamine; β-PEA, β-phenylethylamine; mTAAR1, murine Trace-Amine Associated-Receptor 1;

References

1. Scanlan, T. S.; Suchland, K. L.; Hart, M. E.; Chiellini, G.; Huang, Y.; Kruzich, P. J.; Frascarelli, S.; Crossley, D. A.; Bunzow, J. R.; Ronca-Testoni, S. 3-Iodothyronamine is an endogenous and rapid-acting derivative of thyroid hormone. *Nat. Med.* **2004,** *10*, 638-642.

2. Scanlan, T. S. 3-Iodothyronamine (T(1)AM): a new player on the thyroid endocrine team? *Endocrinology* **2009,** *150*, 1108-1111.

3. Braulke, L. J.; Klingenspor, M.; DeBarber, A.; Tobias, S. C.; Grandy, D. K.; Scanlan, T. S.; Heldmaier, G. 3-Iodothyronamine: a novel hormone controlling the balance between glucose and lipid utilisation. *J. Comp. Physiol. B* **2008,** *178*, 167-177.

4. Chiellini, G.; Nesi, G.; Digiacomo, M.; Malvasi, R.; Espinoza, S.; Sabatini, M.; Frascarelli, S.; Laurino, A.; Cichero, E.; Macchia, M.; Gainetdinov, R. R.; Fossa, P.; Raimondi, L.; Zucchi, R.; Rapposelli, S. Design, synthesis, and evaluation of thyronamine analogues as novel potent mouse Trace Amine Associated Receptor 1 (mTAAR1) Agonists. *J. Med. Chem.* **2015,** *58*, 5096-5107.

5. Chiellini, G.; Rapposelli, S.; Zucchi, R. Synthetic analogues of 3-iodothyronamine (t1am) and uses thereof. WO2015151068A1, 2015.

6. Hoefig, C. Thyroid hormone metabolites in cardiovascular health and disease. *A Symposium on the Occasion of the Centennial Anniversary of Thyroxine Discovery yroid hormone metabolites in cardiovascular health and disease.* Delphi, Greece, June 11, **2015**.

7. Espinoza, S.; Masri, B.; Salahpour, A.; Gainetdinov, R. R. BRET approaches to characterize dopamine and TAAR1 receptor pharmacology and signaling. *Methods Mol. Biol.* **2013,** *964*, 107-122.

8. Cichero, E.; Espinoza, S.; Gainetdinov, R. R.; Brasili, L.; Fossa, P. Insights into the structure and pharmacology of the human Trace Amine-Associated Receptor 1 (hTAAR1): homology modelling and docking studies. *Chem. Biol. Drug Des.* **2013,** *81*, 509-516.

9. Cichero, E.; Espinoza, S.; Franchini, S.; Guariento, S.; Brasili, L.; Gainetdinov, R. R.; Fossa, P. Further insights into the pharmacology of the human Trace Amine-Associated Receptors: discovery of novel ligands for TAAR1 by a virtual screening approach. *Chem. Biol. Drug Des.* **2014,** *84*, 712-720.

10. Cichero, E.; Espinoza, S.; Tonelli, M.; Franchini, S.; Gerasimov, A. S.; Sorbi, C.; Gainetdinov, R. R.; Brasili, L.; Fossa, P. A homology modelling-driven study leading to the discovery of the first mouse trace amine-associated receptor 5 (TAAR5) antagonists. *MedChemComm* **2016,** *7*, 353-364.

11. Wainscott, D. B.; Little, S. P.; Yin, T.; Tu, Y.; Rocco, V. P.; He, J. X.; Nelson, D. L. Pharmacologic characterization of the cloned human trace amine-associated receptor1 (TAAR1) and evidence for species differences with the rat TAAR1. *J. Pharmacol. Exp. Ther.* **2007,** *320*, 475-485.

12. Reese, E. A.; Norimatsu, Y.; Grandy, M. S.; Suchland, K. L.; Bunzow, J. R.; Grandy, D. K. Exploring the determinants of trace amine-associated receptor 1's functional selectivity for the stereoisomers of amphetamine and methamphetamine. *J. Med. Chem.* **2014,** *57*, 378-390.

13. Regard, J. B.; Kataoka, H.; Cano, D. A.; Camerer, E.; Yin, L.; Zheng, Y.-W.; Scanlan, T. S.; Hebrok, M.; Coughlin, S. R. Probing cell type–specific functions of Gi in vivo identifies GPCR regulators of insulin secretion. *J. Clin. Invest.* **2007,** *117*, 4034-4043.

14. Klieverik, L. P.; Foppen, E.; Ackermans, M. T.; Serlie, M. J.; Sauerwein, H. P.; Scanlan, T. S.; Grandy, D. K.; Fliers, E.; Kalsbeek, A. Central effects of thyronamines on glucose metabolism in rats. *J. Endocrinol.* **2009,** *201*, 377-386.

15. Manni, M. E.; De Siena, G.; Saba, A.; Marchini, M.; Dicembrini, I.; Bigagli, E.; Cinci, L.; Lodovici, M.; Chiellini, G.; Zucchi, R. 3-Iodothyronamine: a modulator of the hypothalamus-pancreas-thyroid axes in mice. *Br. J. Pharmacol.* **2012,** *166*, 650-658.

16. Ghelardoni, S.; Chiellini, G.; Frascarelli, S.; Saba, A.; Zucchi, R. Uptake and metabolic effects of 3-iodothyronamine in hepatocytes. *J. Endocrinol.* **2014,** *221*, 101-110.

17. Rosenbaum, D. M.; Zhang, C.; Lyons, J. A.; Holl, R.; Aragao, D.; Arlow, D. H.; Rasmussen, S. G.; Choi, H.-J.; DeVree, B. T.; Sunahara, R. K. Structure and function of an irreversible agonist-[bgr] 2 adrenoceptor complex. *Nature* **2011,** *469*, 236-240.

18. *Sybyl, X.* 1.0 Tripos Inc 1699 South Hanley Road. St Louis. Missouri 63144.

19. Barak, L. S.; Salahpour, A.; Zhang, X.; Masri, B.; Sotnikova, T. D.; Ramsey, A. J.; Violin, J. D.; Lefkowitz, R. J.; Caron, M. G.; Gainetdinov, R. R. Pharmacological characterization of membrane-expressed human trace amine-associated receptor 1 (TAAR1) by a bioluminescence resonance energy transfer cAMP biosensor. *Mol. Pharmacol.* **2008,** *74*, 585-594.

20. Salahpour, A.; Espinoza, S.; Masri, B.; Lam, V.; Barak, L. S.; Gainetdinov, R. R. BRET biosensors to study GPCR biology, pharmacology, and signal transduction. *Front. Endocrinol. (Lausanne)* **2012,** *3*, 105.

TOC Graphic.


Pharmacophore Exploration
Lead Compound (SG2)
EC50 = 240 nM
1: EC50 = 119 nM
2: EC50 = 98 nM
4: EC50 = 158 nM
8: EC50 = 102 nM